STOCK TITAN
  1. Home
  2. News
  3. AMRN

Amarin - AMRN STOCK NEWS

Welcome to our dedicated page for Amarin news (Ticker: AMRN), a resource for investors and traders seeking the latest updates and insights on Amarin stock.

Amarin Corporation plc (AMRN) delivers innovative cardiovascular therapeutics through advanced lipid science, anchored by its FDA-approved therapy VASCEPA®. This page provides direct access to official company announcements, clinical research updates, and regulatory developments.

Investors and healthcare professionals will find curated press releases covering drug approvals, global expansion efforts, and peer-reviewed study results. Key updates include milestones from the landmark REDUCE-IT trial, intellectual property developments, and strategic partnerships enhancing patient access to cardiovascular care solutions.

All content is sourced from Amarin's corporate communications, ensuring accuracy and timeliness. Bookmark this page for streamlined tracking of AMRN's progress in addressing persistent cardiovascular risk through scientifically validated therapies.

News

Amarin Appoints Jonathan Provoost Executive Vice President, Chief Legal & Compliance Officer

Rhea-AI Summary
Amarin Corporation plc has appointed Jonathan Provoost as its new Executive Vice President, Chief Legal & Compliance Officer. Provoost brings over 20 years of corporate legal experience, having served in various leadership roles in pharmaceutical companies. He will join Amarin on November 15.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.45%
Tags
management
-
News

Latest Research Evaluating VASCEPA®/VAZKEPA® (icosapent ethyl) and Subgroups from the REDUCE-IT Landmark Outcomes Trial to be Presented at the American Heart Association (AHA) Scientific Sessions 2023

Rhea-AI Summary
Amarin announces new research from the REDUCE-IT trial on the effects of VASCEPA/VAZKEPA in high-risk patient subgroups. The research includes reduction in CV events in patients with Metabolic Syndrome but without diabetes, mechanistic analyses of EPA and DHA, and demographic/clinical characteristics of US patients with diabetes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.82%
Tags
none
-
News

 Amarin to Report Third Quarter 2023 Financial Results and Host Conference Call on November 1, 2023

Rhea-AI Summary
Amarin Corporation to host conference call to discuss Q3 2023 financial results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.9%
Tags
conferences earnings
News

Amarin to Present at the 2023 Cantor Global Healthcare Conference

Rhea-AI Summary
Amarin CEO to participate in Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
conferences
-
News

Amarin Provides Pricing & Reimbursement Updates for VAZKEPA (icosapent ethyl) in The Netherlands and Italy

Rhea-AI Summary
Amarin Corporation announced pricing and reimbursement updates for VAZKEPA in the Netherlands and Italy. The Dutch Ministry of Health has approved VAZKEPA for national reimbursement to reduce the risk of cardiovascular events in statin-treated patients with established cardiovascular disease and elevated triglycerides. In Italy, AIFA has issued a decision to not reimburse VAZKEPA at this time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.31%
Tags
none
-
News

Amarin And Neopharm Announce Exclusive Commercialization Agreement for VAZKEPA® (Icosapent Ethyl) in Israel

Rhea-AI Summary
Amarin Corporation and Neopharm Israel have entered into an exclusive marketing and commercialization agreement for VAZKEPA in Israel. VAZKEPA is the first prescription treatment comprised solely of icosapent ethyl, a highly purified form of eicosapentaenoic acid. The agreement follows regulatory approval by Israel's Ministry of Health for VAZKEPA to reduce the risk of cardiovascular events in high-risk patients with elevated triglycerides. Heart disease is the second leading cause of death in Israel for individuals aged 45 and older.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.74%
Tags
none
News

Scottish Medicines Consortium Accepts VAZKEPA® (icosapent ethyl) to Help Reduce Cardiovascular Risk for Patients in Scotland(1)

Rhea-AI Summary
Amarin Corporation plc (NASDAQ:AMRN) announces SMC acceptance of VAZKEPA® for reimbursement in Scotland for secondary prevention in high-risk statin-treated patients with established cardiovascular disease. The innovative treatment option aims to reduce the risk of subsequent cardiovascular events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.54%
Tags
none
-
News

Amarin Reports Second Quarter 2023 Financial Results

Rhea-AI Summary
Amarin Corporation reported total net revenues of $80 million in the second quarter of 2023, with net product revenues of $65 million and $15 million in license and royalty revenues. The company achieved positive cash flow of $9 million and has a cash position of $313 million. They implemented a cost reduction plan expected to save $40 million over 12 months. The Spanish Drug Pricing Committee recommended national reimbursement of VAZKEPA® in Spain. U.S. product net revenue declined by 22% sequentially to $64.6 million. Amarin is actively filing regulatory submissions for approval in 20 additional countries.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News

Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea

Rhea-AI Summary
Amarin Corporation and Lotus Pharmaceuticals have formed a partnership to distribute and commercialize VAZKEPA across 10 countries, including nine in Southeast Asia and South Korea. VAZKEPA is an innovative treatment option to reduce cardiovascular risk. The partnership will help Amarin expand patient access to VAZKEPA and fuel international growth. The ASEAN region and South Korea have a total hyperlipidemia market of approximately $2 billion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
partnership
News

Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
none
Stock AMRN logo
Amarin

Nasdaq:AMRN

AMRN Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

AMRN Stock Data

188.66M
20.55M
1.63%
18.07%
4.08%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
Ireland
DUBLIN 2